Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project
- PMID: 35063114
- PMCID: PMC8789563
- DOI: 10.1016/S2214-109X(21)00518-0
Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: a 3-year, systematic, post-mortem surveillance project
Abstract
Background: Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections and a key driver of childhood mortality. Previous RSV burden of disease estimates used hospital-based surveillance data and modelled, rather than directly measured, community deaths. Given this uncertainty, we conducted a 3-year post-mortem prevalence study among young infants at a busy morgue in Lusaka, Zambia-the Zambia Pertussis RSV Infant Mortality Estimation (ZPRIME) study.
Methods: Infants were eligible for inclusion if they were aged between 4 days and less than 6 months and were enrolled within 48 h of death. Enrolment occurred mainly at the University Teaching Hospital of the University of Zambia Medical School (Lusaka, Zambia), the largest teaching hospital in Zambia. We extracted demographic and clinical data from medical charts and official death certificates, and we conducted verbal autopsies with the guardian or next of kin. RSV was identified using reverse transcriptase quantitative PCR and stratified by age, time of year, and setting (community vs facility deaths). By combining the PCR prevalence data with syndromic presentation, we estimated the proportion of all infant deaths that were due to RSV.
Findings: The ZPRIME study ran from Aug 31, 2017, to Aug 31, 2020, except for from April 1 to May 6, 2020, during which data were not collected due to restrictions on human research at this time (linked to COVID-19). We enrolled 2286 deceased infants, representing 79% of total infant deaths in Lusaka. RSV was detected in 162 (7%) of 2286 deceased infants. RSV was detected in 102 (9%) of 1176 community deaths, compared with 10 (4%) of 236 early facility deaths (<48 h from admission) and 36 (5%) of 737 late facility deaths (≥48 h from admission). RSV deaths were concentrated in infants younger than 3 months (116 [72%] of 162 infants), and were clustered in the first half of each year and in the poorest and most densely populated Lusaka townships. RSV caused at least 2·8% (95% CI 1·0-4·6) of all infant deaths and 4·7% (1·3-8·1) of community deaths.
Interpretation: RSV was a major seasonal cause of overall infant mortality, particularly among infants younger than 3 months of age. Because most RSV deaths occurred in the community and would have been missed through hospital-based surveillance, the global burden of fatal RSV has probably been underestimated.
Funding: Bill & Melinda Gates Foundation.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests CJG and LM report grants from the US National Institutes of Health and from Merck, paid to Boston University. CJG also reports receiving fees for participation on data safety and monitoring boards for Takeda, Moderna, and CureVac, all outside the submitted work. LM reports receiving financial support from the Bill & Melinda Gates Foundation to attend meetings on respiratory syncytial virus. RL reports research awards from Pfizer, paid to her institution, and honoraria for participation in pneumococcal advisory boards and consulting fees from Pfizer, paid to her, outside the submitted work. AL reports employment with Manpower Professional Services, which was contracted by Merck to complete work for the Global Vaccines Public Policy & Partnerships team, and fees from Merck for consultancy services, outside the submitted work. All other authors declare no competing interests.
Figures


Comment in
-
Deaths from RSV in young infants-the hidden community burden.Lancet Glob Health. 2022 Feb;10(2):e169-e170. doi: 10.1016/S2214-109X(21)00558-1. Lancet Glob Health. 2022. PMID: 35063106 No abstract available.
Similar articles
-
Risk Factors for Respiratory Syncytial Virus-Associated Community Deaths in Zambian Infants.Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S187-S192. doi: 10.1093/cid/ciab453. Clin Infect Dis. 2021. PMID: 34472570 Free PMC article.
-
Association of Respiratory Syncytial Virus Infection and Underlying Risk Factors for Death Among Young Infants Who Died at University Teaching Hospital, Lusaka Zambia.Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S180-S186. doi: 10.1093/cid/ciab466. Clin Infect Dis. 2021. PMID: 34472569 Free PMC article.
-
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19. Lancet. 2022. PMID: 35598608 Free PMC article. Review.
-
Postmortem Nasopharyngeal Microbiome Analysis of Zambian Infants With and Without Respiratory Syncytial Virus Disease: A Nested Case Control Study.Pediatr Infect Dis J. 2023 Aug 1;42(8):637-643. doi: 10.1097/INF.0000000000003941. Epub 2023 Jul 13. Pediatr Infect Dis J. 2023. PMID: 37093853 Free PMC article.
-
Deaths Attributed to Respiratory Syncytial Virus in Young Children in High-Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS).Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S218-S228. doi: 10.1093/cid/ciab509. Clin Infect Dis. 2021. PMID: 34472577 Free PMC article.
Cited by
-
Using Minimally Invasive Tissue Sampling and Determination of Cause of Death to Establish Etiologies of Community Respiratory Deaths Among Zambian Infants and Children.J Pediatric Infect Dis Soc. 2025 Jan 20;14(1):piae129. doi: 10.1093/jpids/piae129. J Pediatric Infect Dis Soc. 2025. PMID: 39786450
-
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.JAMA Netw Open. 2023 Feb 1;6(2):e230023. doi: 10.1001/jamanetworkopen.2023.0023. JAMA Netw Open. 2023. PMID: 36800182 Free PMC article.
-
Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies.Infect Drug Resist. 2023 Jan 27;16:595-605. doi: 10.2147/IDR.S373584. eCollection 2023. Infect Drug Resist. 2023. PMID: 36733921 Free PMC article. Review.
-
Estimates of the national burden of respiratory syncytial virus in Kenyan children aged under 5 years, 2010-2018.BMC Med. 2023 Mar 31;21(1):122. doi: 10.1186/s12916-023-02787-w. BMC Med. 2023. PMID: 37004034 Free PMC article.
-
Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Vaccines (Basel). 2024 Aug 2;12(8):879. doi: 10.3390/vaccines12080879. Vaccines (Basel). 2024. PMID: 39204005 Free PMC article. Review.
References
-
- Bryce J, Boschi-Pinto C, Shibuya K, Black RE, Group WHOCHER WHO estimates of the causes of death in children. Lancet. 2005;365:1147–1152. - PubMed
-
- Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415–425. - PubMed
-
- O'Brien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015;15:1398–1408. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous